Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Noosa News22 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business23 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
Business19 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
General22 hours agoA stitch in crime • Inside Story